| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 922,857 | 1,317,980 | ||
| General and administrative | 1,020,154 | 1,143,249 | ||
| Total operating expenses | 1,943,011 | 2,461,229 | ||
| Loss from operations | -1,943,011 | -2,461,229 | ||
| Change in fair value of warrant liability | -611 | -44 | ||
| Other income (expense), net | 35,224 | 16,803 | ||
| Total other income (expense), net | 35,835 | 16,847 | ||
| Net loss | -1,907,176 | -2,444,382 | ||
| Deemed dividends | 2,769,742 | 3,181,786 | ||
| Net loss attributable to common stockholders | -4,676,918 | -5,626,168 | ||
| Earnings per share, basic, total | -1.77 | -7.01 | ||
| Earnings per share, diluted | -1.77 | -7.01 | ||
| Weighted average number of shares outstanding, basic, total | 2,644,733 | 802,670 | ||
| Weighted average number of shares outstanding, diluted | 2,644,733 | 802,670 | ||
REVELATION BIOSCIENCES, INC. (REVBW)
REVELATION BIOSCIENCES, INC. (REVBW)